A National Institutes of Health employee who was fired after alleging scientific misconduct and sexual harassment in federal AIDS research has been reinstated.

Dr. Jonathan Fishbein's firing started a two-year fight to get his job back and promoted both congressional and federal investigations, reports The Associated Press

Georgia has suspended the license of a doctor charged with treating cancer patients with injections of weed killer. Totada R. Shanthaveerappa has been indicted on federal charges that include insurance fraud, the Atlanta Journal-Constitution reported. The 87-count indictment alleges that he used unapproved treatments and filed false reports to get insurance reimbursement.

The state medical board on Friday suspended the license of a doctor accused of treating patients with a chemical used in pesticides and reported that one of his patients died after receiving a high dose of a chemotherapy drug. The board suspended Dr. Shanthaveerappa's license, saying his continued practice of medicine "poses a threat to the public health, safety and welfare" and "requires emergency action

A National Institutes of Health employee who was fired after alleging scientific misconduct and sexual harassment in federal AIDS research has been reinstated.

Dr. Jonathan Fishbein's firing started a two-year fight to get his job back and promoted both congressional and federal investigations, reports The Associated Press

Researchers have found that older adults can respond to behavioral treatments for insomnia.

It was thought that the elderly may be less responsive to behavioral approaches for chronic sleep problems. However, an analysis of 23 studies found this is not true, says researcher Michael Irwin, a professor of psychiatry at UCLA

A federal judge on Friday upheld the validity of two key U.S. patents on Pfizer Inc.'s Lipitor cholesterol drug, blocking a generic version of the medicine that threatened the company's largest source of revenue. The decision, which lifted Pfizer shares 10 percent, dealt a setback to Indian drug maker Ranbaxy Laboratories Ltd which had hoped to introduce the cheaper copycat as soon as 2008. Pfizer will now have patent protection on the world's best-selling drug through June 2011. Ranbaxy vowed to appeal the decision.

Lipitor is Pfizer's pillar of strength as the company's revenue growth and earnings continue to dwindle due to a raft of problems. Sales of Pfizer's Celebrex have been cut almost in half due to safety concerns. Revenue from Bextra was eliminated when the drug was withdrawn after being linked to a deadly skin condition